



CASE: LA0112 NP

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\_\_\_\_\_  
Burton Rodney  
Type or print name

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date  
September 26 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**IN RE APPLICATION OF**

**ART UNIT: 1626**

**TIMUR GUNGOR, ET AL.**

**EXAMINER: STOCKTON, LAURA LYNNE**

**APPLICATION NO: 10/775,742**

**FILED: 02/10/2004**

**FOR: NOVEL THIAZOLIDINE COMPOUNDS AS CALCIUM  
SENSING RECEPTOR MODULATORS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DECLARATION OF ZHENGPING MA**

To the Commissioner for Patents and Trademarks:

**ZHENGPING MA DECLARES AS FOLLOWS:**

1. She has a Master's degree in Biology and acquainted with testing of chemical compounds for activity as a modulator of the calcium sensing receptor employing test protocol.
  
2. She was employed at Bristol-Myers Squibb Company under the supervision of Dr. Ramakrishna Seethala.

**BEST AVAILABLE COPY**

3. That prior to October 22, 2001, she received a sample of the compound of Example 1 of the subject application which was sent from Dr. Ramakrishna Seethala, Department of Metabolic Diseases, Age Related Diseases and Bone Biology for testing of such compound as a modulator of the calcium receptor.

4. In Notebook No. 49,513, page 079-081, 083 and 084 (ATTACHMENT K through Q, including cover page and table of contents), Zhengping Ma, under the supervision of Dr. Ramakrishna Seethala, recorded experiments concerning the testing of the compound of Example 1 as a modulator of the calcium sensing receptor.

All of Notebook No. 49,513, pages 079-081, 083 and 084 were signed by Zhengping Ma and witnessed by Yong Quan prior to October 22, 2001.

5. The testing of the compound of Example 1 for its activity in modulating the calcium sensing receptor was carried out as follows:

#### Calcium Receptor Inhibitor Assay Methods:

##### Inhibition of intracellular calcium:

Calcilytic activity was measured in human TT cells (ATCC No. CRL-1083) by determining the IC50 of the test compound for blocking increases in intracellular Ca<sup>2+</sup> by extracellular Ca<sup>2+</sup> (as agonist of the receptor). Intracellular Ca<sup>2+</sup> was measured using Fluo3,AM (Molecular probes, # F-1242) as indicator dye. Intracellular Ca<sup>2+</sup> increase was measured with extracellular Ca<sup>2+</sup> from 0.5 to 5 mM in Fluorescence Imaging Plate Reader (FLIPR) (Molecular Devices).

The Ca<sup>2+</sup> receptor inhibitor assay procedure is as follows: TT cells were maintained in T-150 flasks in cell growth medium (F-12K Nutrition Media (Gibco 211270-022) with 10% heat inactivated FBS, and 1x Glutamax) in 5% CO<sub>2</sub>:95% air at 37°C to 90% confluence. The medium was removed, the cell monolayer was washed with phosphate buffered saline (PBS), incubated with 0.05% trypsin at 37°C for 2 minutes and the cells were dispensed by agitation. Cells from 2 flasks were pooled and centrifuged (200xg). The cell pellet was suspended in cell growth medium. Cells were plated 30,000 cells/well for 2 days, or 24,000 cells/well for 3 days in 96-well black view plates

(Falcon, VWR#624-06-468) and incubated in 5% CO<sub>2</sub>:95% air at 37°C. Cell medium was aspirated, and cells were loaded with Fluo3 (Molecular Probes, 50 µg dissolved in 25 µl DMSO, 50 µl 20% Pluronic Acid) in base buffer (10 mM HEPES buffer containing 1x Hank's salt, 0.1% BSA, 0.05% D-glucose, 0.8 mM CaCl<sub>2</sub>) or 1 hour in a 37°C incubator. After incubation, loading buffer was aspirated and 120 µl/well base buffer was added.

Drug plates were prepared in base buffer and loaded into FLIPR. 30 µl from drug plate was added to the cell assay plate and fluorescence signals were read in FLIPR. Drug plate was replaced with CaCl<sub>2</sub> plate in FLIPR plate draw and 30 µl CaCl<sub>2</sub> (1.7 mM final for IC50s, or 2.0 mM for screening) was added into cell plate by FLIPR. The fluorescence signal was measured by reading at 1 second intervals for 30 seconds and at 3 second intervals for the next 150 seconds. Calcilytic activity of the compounds was measured by their ability to block, in a concentration dependent manner (half-log concentrations in triplicate), the intracellular Ca<sup>2+</sup> level by extracellular 1.7 mM Ca<sup>2+</sup>. The data was processed by ActivityBase (IDDBS) and the IC50 values are determined by protocols developed.

6. A summary of the test results obtained by Zhengping Ma (prior to October 22, 2001) is set out in a summary sheet (ATTACHMENT R) prepared after October 22, 2001.

7. The actual dates of Experiments regarding the testing of the Example 1 compound recorded in Notebook No. 49,513, pages 079-081, 083 and 084 were carried out and the dates of signing by Zhengping Ma and witnessing by Yong Quan, were all prior to October 22, 2001, but have been obliterated.

8. Other non-relevant portions of Notebook No. 49,513, pages 079-081, 083 and 084 which did not relate to the testing of Example 1 compound were obliterated.

9. This Declaration is submitted prior to Final Rejection.

10. The undersigned declares further that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true;

and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of application Serial No. 10/775,742 or any patent issued thereon.

Date:

9/20/2006

Zhengping Ma  
ZHENGPING MA

BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE

BRISTOL-MYERS SQUIBB

NOTEBOOK No. 49513

Assigned to

*Zhengping Ma*

Subject

Department Name

*Aging Research*

Department Number

*800 1602*

Date Assigned

Date Completed

Pages Completed from

*671*

to *250*

Continued from Notebook Number

*49423*

Continued in Notebook Number

*51731*

Caution

Proprietary and confidential information of Bristol-Myers Squibb Company

Do not disclose or reproduce without proper written authorization

This notebook cannot be transferred to another person

ATTACHMENT K

## TABLE OF CONTENTS

U9513

PROJECT OR EXPERIMENT NO.	PRODUCT OR SUBSTANCE	STUDY PERFORMED OR OBJECTIVE	PAGES
------------------------------	----------------------	------------------------------	-------

IC50s: BMS-515832-02-002, 280429, 280581

C3R response in TT cells

49513-079

49513-088

## BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE

49513 072

NOTEBOOK No. PAGE

CaR response in T1 cells

T1 cells plated on at 24,000 cells/well used (see also 49513-068)  
0.8 mM Ca<sup>++</sup> basal, 1.7 mM Ca<sup>++</sup> stimulation.  
See also 44676-072 for basic protocol.

Plate J

BMS-515832-02-002 (uM) (A1-C6)

synthesis

	1	2	3	4	5	6
A	1.0000	0.3333	0.1111	0.0370	0.0123	0.0041
B	1.0000	0.3333	0.1111	0.0370	0.0123	0.0041
C	1.0000	0.3333	0.1111	0.0370	0.0123	0.0041

ATTACHMENT M

SIGNED

Bengt M

DATE

WITNESSED AND UNDERSTOOD BY

DATE

Signature

## BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE

NOTES/OK/N0. 15 15

PAGE

Signal Test

Continued

SI

Plate 1 ZMCa072601a\_n0  
Minimum 9045.6 -16.47%  
Average 10829.4Maximum 12823.2  
STDEV 738.3

	1	2	3	4	5	6
A	11194.4	10826.4	10314.4	10444.0	10192.8	9940.0
B	10764.0	11074.4	10508.0	9893.6	9832.8	9298.4
C	9922.4	11116.0	10592.8	10845.6	10831.2	10120.8

ATTACHMENT  
A

SIGNED

Shengyj Ma

DATE

WITNESSED AND UNDERSIGNED


DATE

40543 031

NOTEBOOK No. PAGE

*Continued*

Z14Ca072501a\_nt.fid



Range = (-1000,19000)

WITNESSED AND UNDERSTOOD BY:

DATE

*ATTACHMENT C**Zhengyu Ma**[Signature]*

## BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE

49613 083

NOTEBOOK NO. PAGE

Continued

File = D:\mazhi\ZMCa\972601a\_n1.fid

Statistic = Max - Min

Start Sample = 11 End Sample = 45

Positive Scaling = On Negative Correction = Off

Bias Value Subtract = On Spatial Uniformity Correction = On

Bias Sample = 1

Plate 1

	A	B	C	D	E	F	G	H
1	3.79	4.98	2.39	43.82	15.28	26.01	2.4	3.96
2	4.56	4.47	3.85	60.51	45.13	65.27	4.92	3.28
3	11.06	12.77	17.3	95.26	62.57	82.4	20.93	11.91

ATTACHMENT P


SIGNED

Shengjie Ma

DATE

WITNESSED AND UNDERSTOOD BY

DATE



## BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE

49513 084


NOTEBOOK NO. PAGE

*Continued*

Test Occasion ID: MDCaR010726-1  
 Protocol ID: CaR\_H\_IC50  
 Study ID: CaR  
 User ID: Zhengping Ma

-Plate 1

Compound ID	Conc (pM)	% TL1	% TL2	% TL3	% AVERAGE	SDev	IC50
BMS-515832-02-002	1.000	3.79	4.98	2.99	3.72	1.30	0.024321
	0.333	4.56	4.47	3.85	4.29	0.39	0.115
	0.111	11.06	12.77	17.3	13.71	3.22	1.15
	0.037	32.3	43.99	44.12	40.14	6.79	
	0.012	56.51	49.98	99.99	68.53	27.51	
	0.004	41.18	51.95	37.58	46.90	13.16	



Done Response

SIGNED

Zhengping Ma


DATE

WITNESSED AND UNDERSTOOD BY

DATE

*ATTACHMENT Q**[Signature]*

Pcris.db



Library Name	Test Occasion	Test Occasion Notes	Parent_Study
	MDCaR010726-1 MDCaR010726-1		
Alliance ID	MDCaR010726-1 MDCaR010809 MDCaR010816		

ATTACHMENT R

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**